The emerging roles of Notch signaling in leukemia and stem cells

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Liu, Na ^a   Zhang, Jingru ^a   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CD14 ANTIGEN; CYCLIN A; CYCLIN D1; DELTA LIKE PROTEIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 7; JAGGED1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAMMALIAN TARGET OF RAPAMYCIN; MICROSOMAL AMINOPEPTIDASE; MK 0752; MYC PROTEIN; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LEUKEMIA; CANCER INHIBITION; CANCER STEM CELL; GASTROINTESTINAL TOXICITY; HUMAN; LEUKEMIA; LYMPHATIC LEUKEMIA; MYELOID LEUKEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; T CELL LEUKEMIA; TUMOR MICROENVIRONMENT;

EID: 84907023750     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-23     Document Type: Review

References (77)

1. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013, 34(7):1420-1430. 10.1093/carcin/bgt127, 23585460.
2. Del Amo FF, Smith DE, Swiatek PJ, Gendron-Maguire M, Greenspan RJ, McMahon AP, Gridley T. Expression pattern of Motch, a mouse homolog of Drosophila Notch, suggests an important role in early postimplantation mouse development. Development 1992, 115(3):737-744.
3. Weinmaster G, Roberts VJ, Lemke G. Notch2: a second mammalian Notch gene. Development 1992, 116(4):931-941.
4. Lardelli M, Dahlstrand J, Lendahl U. The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium. Mech Dev 1994, 46(2):123-136. 10.1016/0925-4773(94)90081-7, 7918097.
5. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, Kitajewski J. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 1996, 122(7):2251-2259.
6. Fehon RG, Kooh PJ, Rebay I, Regan CL, Xu T, Muskavitch MA, Artavanis-Tsakonas S. Molecular interactions between the protein products of the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila. Cell 1990, 61(3):523-534. 10.1016/0092-8674(90)90534-L, 2185893.
7. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003, 194(3):237-255. 10.1002/jcp.10208, 12548545.
8. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cellular and molecular life sciences: CMLS 2009, 66(10):1631-1646. 10.1007/s00018-009-8668-7, 19165418.
9. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, Guo Z, Cheng T, Cao X. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003, 63(23):8323-8329.
10. Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B, Axelson H. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008, 118(1):217-228. 10.1172/JCI32086, 2129233, 18079963.
11. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998, 18(4):2077-2088. 121438, 9528780.
12. Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 2002, 9(8):842-855. 10.1038/sj.cdd.4401036, 12107827.
13. Hales EC, Orr SM, Larson Gedman A, Taub JW, Matherly LH. Notch1 regulates AKT activation loop (T308) dephosphorylation through modulation of the PP2A phosphatase in PTEN-null T-cell acute lymphoblastic leukemia cells. J Biol Chem 2013, [Epub ahead of print].
14. Pajvani UB, Qiang L, Kangsamaksin T, Kitajewski J, Ginsberg HN, Accili D. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013, [Epub ahead of print].
15. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res 2011, 71(18):6010-6018. 10.1158/0008-5472.CAN-11-0595, 3174331, 21803744.
16. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 20(15):2096-2109. 10.1101/gad.1450406, 1536060, 16847353.
17. Lee JB, Werbowetski-Ogilvie TE, Lee JH, McIntyre BA, Schnerch A, Hong SH, Park IH, Daley GQ, Bernstein ID, Bhatia M. Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embyronic and induced pluripotent cells. Blood 2013, [Epub ahead of print].
18. Murai K, Philpott A, Jones PH. Hes6 is required for the neurogenic activity of neurogenin and NeuroD. PLoS One 2011, 6(11):e27880. 10.1371/journal.pone.0027880, 3218063, 22114720.
19. Li Y, Zhang J, Zhang L, Si M, Yin H, Li J. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis 2013, 34(7):1601-1610. 10.1093/carcin/bgt065, 23430952.
20. Thomas JL, Baker K, Han J, Calvo C, Nurmi H, Eichmann AC, Alitalo K. Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. Cellular and molecular life sciences: CMLS 2013, 70(10):1779-1792. 10.1007/s00018-013-1312-6, 23479133.
21. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006, 66(5):2778-2784. 10.1158/0008-5472.CAN-05-4281, 16510599.
22. Zang S, Chen F, Dai J, Guo D, Tse W, Qu X, Ma D, Ji C. RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol Rep 2010, 23(4):893-899.
23. Miyamoto S, Nakanishi M, Rosenberg DW. Suppression of colon carcinogenesis by targeting Notch signaling. Carcinogenesis 2013, [Epub ahead of print].
24. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271. 10.1126/science.1102160, 15472075.
25. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP, Ferrando AA. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008, 112(3):733-740. 10.1182/blood-2007-12-130096, 2481531, 18411416.
26. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007, 204(8):1813-1824. 10.1084/jem.20070876, 2118656, 17646409.
27. Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood 2008, 111(1):376-378. 10.1182/blood-2007-02-074690, 17901244.
28. van den Brandt J, Kwon SH, McPherson KG, Petrovic S, Zettl A, Muller-Hermelink HK, Reichardt HM. Unexpected features of acute T lymphoblastic lymphomas in Notch1IC transgenic rats. Eur J Immunol 2006, 36(8):2223-2234. 10.1002/eji.200535791, 16838279.
29. Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006, 107(6):2540-2543. 10.1182/blood-2005-07-3013, 1414627, 16282337.
30. Zou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu X, Sun X, Ma D, Park J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol 2013, 6:3. 10.1186/1756-8722-6-3, 3544631, 23289374.
31. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC, Frati L, et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A 2002, 99(6):3788-3793. 10.1073/pnas.062050599, 122602, 11891328.
32. Xiang J, Ouyang Y, Cui Y, Lin F, Ren J, Long M, Chen X, Wei J, Zhang H. Silencing of Notch3 using shRNA driven by survivin promoter inhibits growth and promotes apoptosis of human T-cell acute lymphoblastic leukemia cells. Clin Lymphoma Myeloma Leuk 2012, 12(1):59-65. 10.1016/j.clml.2011.07.005, 21940234.
33. Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic inactivation of notch-hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One 2013, 8(4):e61807. 10.1371/journal.pone.0061807, 3637323, 23637910.
34. Gothert JR, Brake RL, Smeets M, Duhrsen U, Begley CG, Izon DJ. NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis. Blood 2007, 110(10):3753-3762. 10.1182/blood-2006-12-063644, 17698635.
35. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, Aster JC, Allman D, Pear WS. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005, 106(12):3898-3906. 10.1182/blood-2005-01-0355, 1895093, 16118316.
36. Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, Scupoli MT, Pizzolo G, et al. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 2011, 118(2):380-389. 10.1182/blood-2010-12-326694, 21602525.
37. Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, Zweidler-McKay PA. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood 2011, 117(10):2891-2900. 10.1182/blood-2009-12-253419, 3062299, 21224467.
38. Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D, Sieghart W, Valent P, Zielinski C, Jager U, et al. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2013, 160(5):618-629. 10.1111/bjh.12183, 23278106.
39. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002, 99(10):3742-3747. 10.1182/blood.V99.10.3742, 11986231.
40. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005, 19(2):260-267. 10.1038/sj.leu.2403592, 15565166.
41. Hubmann R, Duchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Holbl A, Vanura K, Le T, Look T, et al. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2010, 148(6):868-878. 10.1111/j.1365-2141.2009.08024.x, 19995395.
42. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I, Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009, 113(4):856-865. 10.1182/blood-2008-02-139725, 18796623.
43. Grieselhuber NR, Klco JM, Verdoni AM, Lamprecht T, Sarkaria SM, Wartman LD, Ley TJ. Notch signaling in acute promyelocytic leukemia. Leukemia 2013, 27(7):1548-1557. 10.1038/leu.2013.68, 23455394.
44. Zhang J, Ma D, Ye J, Zang S, Lu F, Yang M, Qu X, Sun X, Ji C. Prognostic impact of delta-like ligand 4 and Notch1 in acute myeloid leukemia. Oncol Rep 2012, 28(4):1503-1511.
45. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013, 210(2):321-337. 10.1084/jem.20121527, 23359069.
46. Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V, Biondi A, Comi P. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett 2005, 219(1):113-120. 10.1016/j.canlet.2004.07.022, 15694671.
47. Chen PM, Yen CC, Wang WS, Lin YJ, Chu CJ, Chiou TJ, Liu JH, Yang MH. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. Int J Oncol 2008, 32(6):1335-1341.
48. Palomero T, McKenna K, ON J, Galinsky I, Stone R, Suzukawa K, Stiakaki E, Kalmanti M, Fox EA, Caligiuri MA, et al. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006, 20(11):1963-1966. 10.1038/sj.leu.2404409, 17008890.
49. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013, 161(1):117-127. 10.1111/bjh.12231, 23373539.
50. Rakowski LA, Garagiola DD, Li CM, Decker M, Caruso S, Jones M, Kuick R, Cierpicki T, Maillard I, Chiang MY. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias. Cancer Res 2013, 73(2):930-941. 10.1158/0008-5472.CAN-12-1389, 23161489.
51. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, Levy Y, Benkirane M. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell 2012, 48(3):445-458. 10.1016/j.molcel.2012.08.022, 3595990, 23022380.
52. Yamamoto K, Nakamachi Y, Yakushijin K, Miyata Y, Okamura A, Kawano S, Matsuoka H, Minami H. A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34). Eur J Haematol 2013, 90(1):68-75. 10.1111/ejh.12019, 23033986.
53. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473(7346):230-233. 10.1038/nature09999, 3093658, 21562564.
54. Yang Z, Yang C, Zhang S, Li Y, Chen J. Notch2 inhibits proliferation of chronic myeloid leukemia cells. Oncology letters 2013, 5(4):1390-1394. 3629273, 23599800.
55. Yin DD, Fan FY, Hu XB, Hou LH, Zhang XP, Liu L, Liang YM, Han H. Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562. Leuk Res 2009, 33(1):109-114. 10.1016/j.leukres.2008.06.023, 18687467.
56. Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman AV, et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 2013, 27(1):41-47. 10.1038/leu.2012.176, 22814294.
57. Hannon MM, Lohan F, Erbilgin Y, Sayitoglu M, O'Hagan K, Mills K, Ozbek U, Keeshan K. Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL. Br J Haematol 2012, 158(5):626-634. 10.1111/j.1365-2141.2012.09222.x, 22775572.
58. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, et al. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One 2012, 7(6):e39725. 10.1371/journal.pone.0039725, 3387267, 22768113.
59. Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM. Activity of the selective IkappaB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle 2012, 11(13):2467-2475. 10.4161/cc.20859, 22713244.
60. Tzoneva G, Ferrando AA. Recent advances on NOTCH signaling in T-ALL. Curr Top Microbiol Immunol 2012, 360:163-182. 10.1007/82_2012_232, 22673746.
61. Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J. Modulated expression of notch1 during thymocyte development. Blood 1996, 88(3):970-976.
62. Washburn T, Schweighoffer E, Gridley T, Chang D, Fowlkes BJ, Cado D, Robey E. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 1997, 88(6):833-843. 10.1016/S0092-8674(00)81929-7, 9118226.
63. Haydu JE, De Keersmaecker K, Duff MK, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Ferrando A. An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 2012, 119(22):5211-5214. 10.1182/blood-2011-10-388504, 3369611, 22510873.
64. Shelly LL, Fuchs C, Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem 1999, 73(2):164-175. 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0, 10227380.
65. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013, 210(2):301-319. 10.1084/jem.20121484, 23359070.
66. Guo D, Ye J, Li L, Dai J, Ma D, Ji C. Down-regulation of Notch-1 increases co-cultured Jurkat cell sensitivity to chemotherapy. Leuk Lymphoma 2009, 50(2):270-278. 10.1080/10428190802553257, 19160126.
67. Zhang J, Ye J, Ma D, Liu N, Wu H, Yu S, Sun X, Tse W, Ji C. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis 2013, 34(3):667-677. 10.1093/carcin/bgs386, 23239744.
68. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004, 103(9):3503-3510. 10.1182/blood-2003-07-2340, 14670925.
69. Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M, Boissel N, Dombret H, Baruchel A, Landman-Parker J, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113(8):1730-1740. 10.1182/blood-2008-02-138172, 18984862.
70. Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 2007, 92(2):264-266. 10.3324/haematol.10356, 17296584.
71. Winter SS, Sweatman JJ, Lawrence MB, Rhoades TH, Hart AL, Larson RS. Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow stroma requires involvement of LFA-1 and ICAM-1. Br J Haematol 2001, 115(4):862-871. 10.1046/j.1365-2141.2001.03182.x, 11843820.
72. Hatfield K, Ryningen A, Corbascio M, Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. International journal of cancer Journal international du cancer 2006, 119(10):2313-2321. 10.1002/ijc.22180, 16921487.
73. Sharma A, Rangarajan A, Dighe RR. Antibodies against the extracellular domain of human Notch1 receptor reveal the critical role of epidermal-growth-factor-like repeats 25-26 in ligand binding and receptor activation. Biochem J 2013, 449(2):519-530. 10.1042/BJ20121153, 23072667.
74. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464(7291):1052-1057. 10.1038/nature08878, 20393564.
75. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 2012, 58(5):815-818. 10.1002/pbc.23290, 3276746, 22052798.
76. Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, Dallob A, Matthews C, Stone J, Freedman SJ, Aster J. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006, 24(18S). Abstr #6585.
77. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15(1):50-58. 10.1038/nm.1900, 2692090, 19098907.